ENTR-601-51 — IND submission
2026
The Company expects to submit global regulatory applications for ENTR-601-51 in 2026.Source filing
TRDA biotech catalysts & pipeline
ENTRADA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
ENTR-601-51 — NDA/BLA submission
in 2026
The Company expects to submit global regulatory applications to initiate clinical trials for ENTR-601-51 in 2026.Source filing
VX-670 — Topline data
in H2 2026
-- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 --Source filing
ENTR-601-44 — Topline data
Late 2026
Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --Source filing
ENTR-601-50 — IND submission
Late 2026
The Company expects to submit regulatory applications and obtain authorization in the EU for ENTR-601-50 by year-end 2026.Source filing
ENTR-601-45 — Topline data
Oct 2026
-- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 --Source filing
ENTR-601-44 — Topline data
in Q1 2027
-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --Source filing
ENTR-601-45 — Topline data
in H1 2027
-- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 --Source filing